Exploration of Targeted Anti-tumor Therapy

Variables	Primary tumor	Number of patients (%)
T size	≤ 4 cm	3 (12)
> 4 cm but ≤ 7 cm	12 (48)
> 7 cm but ≤ 10 cm	6 (24)
> 10 cm	4 (16)
Histotype	Clear cell	24 (96)
Sarcomatoid	0 (0)
Others	1 (4)
ISUP grade	G1	0 (0)
G2	5 (20)
G3	14 (56)
G4	6 (24)
Vascular invasion	Yes	15 (60)
No	10 (40)
Necrosis	0	9 (36)
1 (+)	5 (20)
2 (++)	7 (28)
3 (+++)	4 (16)

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002165_sup_1.pdf.

Declarations

Author contributions

M Bersanelli: Conceptualization, Investigation, Data curation, Writing—original draft, Writing—review & editing, Supervision. LG: Conceptualization, Investigation, Data curation, Writing—review & editing. FPP: Investigation, Data curation, Writing—review & editing. EV, FQ, NC, ER, and RC: Investigation, Writing—review & editing. PC, EMS, M Rusca, and FL: Investigation, Resources, Writing—review & editing. UM, M Rizzo, and M Brunelli: Investigation, Writing—review & editing. SB and LA: Conceptualization, Investigation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the ethics committee of Parma with reference number 23358, dated 05-jul-2016. The research complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

All datasets for this study are included in the manuscript and the supplementary files.

Funding

Not applicable.

Copyright

References

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399–410. [DOI] [PubMed]

Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol. 2017;8:37–53. [DOI] [PubMed] [PMC]

Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888–98. Erratum in: Lancet Oncol. 2022;23:e319. Erratum in: Lancet Oncol. 202;23:e404. [DOI] [PubMed] [PMC]

Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, et al. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies. Oncologist. 2021;26:476–82. [DOI] [PMC]

Hamieh L, Beck RL, Le VH, Hsieh JJ. The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy. Clin Genitourin Cancer. 2020;18:252–7.E2. [DOI] [PMC]

Escudier B, Porta C, Schmidinger M, Rioux-Leclerq N, Bex A, Khoo V, et al.; ESMO Guidelines Committee. Renal cell carcinoma: ESMO clinical practice guidelines diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:706–20. [DOI] [PubMed]

Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, et al. Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma. Clin Cancer Res. 2022;28:4045–55. [DOI] [PubMed] [PMC]

Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer. 2014;14:376. [DOI] [PubMed] [PMC]

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. Erratum in: N Engl J Med. 2012;367:976. [DOI] [PubMed] [PMC]

10.

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol. 2014;66:936–48. [DOI] [PubMed] [PMC]

11.

Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, et al. Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. Immunotherapy. 2019;11:21–35. Erratum in: Immunotherapy. 2019;11:255. [DOI] [PubMed]

12.

Chen S, Zhu Y, Cui J, Wang Y, Xia Y, Song J, et al. The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review. Urol Oncol. 2017;35:532.e15–23. [DOI] [PubMed]

13.

Macher-Goeppinger S, Keith M, Endris V, Penzel R, Tagscherer KE, Pahernik S, et al. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget. 2017;8:1046–57. [DOI] [PubMed] [PMC]

14.

Campbell L, Jasani B, Griffiths DF, Gumbleton M. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res. 2015;5:2838–48. [PubMed] [PMC]

15.

Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer. 2015;121:43–50. [DOI] [PubMed]

16.

Nishikawa M, Miyake H, Harada KI, Fujisawa M. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol. 2014;31:792. [DOI] [PubMed]